- Home
- RERE vs NPCE Comparison
RERE vs NPCE Comparison
Compare RERE & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- NPCE
- Stock Information
- Founded
- RERE 2011
- NPCE 1997
- Country
- RERE China
- NPCE United States
- Employees
- RERE N/A
- NPCE N/A
- Industry
- RERE Other Specialty Stores
- NPCE Medical Specialities
- Sector
- RERE Consumer Discretionary
- NPCE Health Care
- Exchange
- RERE Nasdaq
- NPCE Nasdaq
- Market Cap
- RERE 444.1M
- NPCE 424.1M
- IPO Year
- RERE 2021
- NPCE 2021
- Fundamental
- Price
- RERE $3.56
- NPCE $9.94
- Analyst Decision
- RERE
- NPCE Buy
- Analyst Count
- RERE 0
- NPCE 7
- Target Price
- RERE N/A
- NPCE $15.14
- AVG Volume (30 Days)
- RERE 2.5M
- NPCE 405.3K
- Earning Date
- RERE 08-19-2025
- NPCE 08-12-2025
- Dividend Yield
- RERE N/A
- NPCE N/A
- EPS Growth
- RERE N/A
- NPCE N/A
- EPS
- RERE 0.07
- NPCE N/A
- Revenue
- RERE $2,388,301,386.00
- NPCE $84,306,000.00
- Revenue This Year
- RERE $27.37
- NPCE $21.04
- Revenue Next Year
- RERE $24.06
- NPCE $10.73
- P/E Ratio
- RERE $49.00
- NPCE N/A
- Revenue Growth
- RERE 26.09
- NPCE 22.05
- 52 Week Low
- RERE $2.00
- NPCE $5.45
- 52 Week High
- RERE $4.35
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- RERE 59.53
- NPCE 36.29
- Support Level
- RERE $3.49
- NPCE $9.91
- Resistance Level
- RERE $4.35
- NPCE $10.58
- Average True Range (ATR)
- RERE 0.29
- NPCE 0.63
- MACD
- RERE 0.03
- NPCE 0.03
- Stochastic Oscillator
- RERE 47.52
- NPCE 19.29
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.